Home › Research › Lewy body dementia
Tau and neurodegenerative disease: the story so far
Iqbal K, Liu F, Gong CX.. Nature reviews. Neurology, 2015-12-04
Topic: Brain proteins, microglia and lab models
Plain-language summary
In 1975, tau protein was isolated as a microtubule-associated factor from the porcine brain. In the previous year, a paired helical filament (PHF) protein had been identified in neurofibrillary tangles in the brains of individuals with Alzheimer disease (AD), but it was not until 1986 that the PHF protein and tau were discovered to be one and the same. In the AD brain, tau was found to be abnormally hyperphosphorylated, and it inhibited rather than promoted in vitro microtubule assembly. Almost 80 disease-causing exonic missense and intronic silent mutations in the tau gene have been found in familial cases of frontotemporal dementia but, to date, no such mutation has been found in AD. The first phase I clinical trial of an active tau immunization vaccine in patients with AD was recently completed. Assays for tau levels in cerebrospinal fluid and plasma are now available, and tau radiotracers for PET are under development. In this article, we provide an overview of the pivotal discoveries in the tau research field over the past 40 years. We also review the current status of the field, including disease mechanisms and therapeutic approaches.
What this study adds
Evidence grade: Low
This is a narrative review. This review notes that almost 80 disease-causing tau gene mutations have been found in familial frontotemporal dementia but none in Alzheimer's disease, and that the first phase I clinical trial of an active tau immunization vaccine in Alzheimer's patients was recently completed. Assays for tau in cerebrospinal fluid and plasma are available, and tau radiotracers for PET are under development.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Iqbal, K., Liu, F., & Gong, C. X. (2016). Tau and neurodegenerative disease: the story so far. Nature reviews. Neurology. https://doi.org/10.1038/nrneurol.2015.225
Vancouver
Iqbal K, Liu F, Gong CX. Tau and neurodegenerative disease: the story so far. Nature reviews. Neurology. 2016. doi:10.1038/nrneurol.2015.225. PMID: 26635213.
BibTeX
@article{iqbal2016-26635213,
author = {Iqbal, K. and Liu, F. and Gong, C. X.},
title = {{Tau and neurodegenerative disease: the story so far}},
journal = {Nature reviews. Neurology},
year = {2016},
doi = {10.1038/nrneurol.2015.225},
pmid = {26635213},
url = {https://doi.org/10.1038/nrneurol.2015.225}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Almost 80 disease-causing exonic missense and intronic silent mutations in the tau gene have been found in familial cases of frontotemporal dementia but, to date, no such mutation has been found in AD.
- The first phase I clinical trial of an active tau immunization vaccine in patients with AD was recently completed.
- Assays for tau levels in cerebrospinal fluid and plasma are now available, and tau radiotracers for PET are under development.
- In this article, we provide an overview of the pivotal discoveries in the tau research field over the past 40 years.
- We also review the current status of the field, including disease mechanisms and therapeutic approaches.
Why it matters
This review notes that almost 80 disease-causing tau gene mutations have been found in familial frontotemporal dementia but none in Alzheimer's disease, and that the first phase I clinical trial of an active tau immunization vaccine in Alzheimer's patients was recently completed. Assays for tau in cerebrospinal fluid and plasma are available, and tau radiotracers for PET are under development.
Study details
- Evidence strengthLow
How this study scored 49/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 48 of the 97 points we could judge it on, which is 49 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Nature reviews. Neurology) |
| Journal's citation record | 3 / 4 | Nature Reviews Neurology: journal h-index 269 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2016 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 809 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 67.4 citations a year over 12 year(s) since 2016 |
| Impact for its field and year | 4 / 6 | Cited 8.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 15 other studies in this library |
| Still being cited | 3 / 4 | Cited 192 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Cheng‐Xin Gong: h-index 81 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 26635213) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 48 / 97 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 48 of the 97 points we could judge it on is 49 out of 100. |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 26.
Later studies that cite this one
15 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Lewy body dementia from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.